Corbus Pharmaceuticals CEO to Present at August Investor Conferences

NORWOOD, Mass., July 30, 2024 - Corbus Pharmaceuticals Holdings, Inc. CRBP ('Corbus' or the 'Company'), a clinical-stage pharmaceutical company specializing in novel therapies targeting the endocannabinoid system, has today announced that Yuval Cohen, Ph.D., the Chief Executive Officer, will be participating in two investor conferences in the month of August. These conferences provide a platform for the Company to engage with potential investors and share updates on the progress and outlook of its drug development programs in autoimmunity, fibrosis, and cancer.

Investor Engagement and Company Growth

Investor conferences are critical for companies like Corbus, allowing them to connect with a broad audience of institutional investors, analysts, and fund managers. Participation in such events is a testament to Corbus’ commitment to maintain transparency with the investment community and to foster relationships that could prove beneficial in supporting the Company's growth objectives. The upcoming investor conferences will feature Dr. Cohen discussing the company's strategic direction, current research, and future goals.

About Corbus Pharmaceuticals

Headquartered in Norwood, Massachusetts, Corbus is at the forefront of clinical-stage drug development. Leveraging its expertise in the endocannabinoid system, Corbus aims to create innovative medical solutions for patients suffering from diseases with high unmet medical needs. The engagement in investor conferences is expected to bring attention to their ongoing efforts in pushing the frontiers of pharmaceutical science in the areas of autoimmunity, fibrosis, and cancer.

Corbus, Pharmaceuticals, Investor